BRIEF

on Adesso AG (ETR:ADN1)

Adesso SE Reports 14% Sales Increase in 2025 Financial Statements

Stock price chart of Adesso AG (EBR:ADN1) showing fluctuations.

Adesso SE has released its consolidated financial statements for 2025, confirming earlier preliminary figures. The company reported a 14% increase in sales, reaching EUR 1.47 billion. EBITDA improved significantly by 30%, amounting to EUR 123.6 million, while earnings per share rose to EUR 2.83 from EUR 0.41 the previous year.

The strong performance is attributed to a robust second half, driven by increased utilization of its workforce and additional license sales in its insurance sector. Adesso's revenue growth outpaced personnel cost rise, resulting in a further improved EBITDA margin of 8.4%.

Sector growth was led by healthcare at 30% and utilities at 24%. Adesso's international operations, particularly in Austria, Italy, and the Netherlands, contributed positively. Despite a 3% revenue decline in Switzerland, the company anticipates a return to growth in 2026.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Adesso AG news